DBV Technologies (NASDAQ:DBVT) Price Target Raised to $45.00

DBV Technologies (NASDAQ:DBVT) had its target price boosted by Citizens Jmp from $21.00 to $45.00 in a report published on Wednesday,Benzinga reports. They currently have a market outperform rating on the stock.

Several other research firms have also commented on DBVT. Cantor Fitzgerald upgraded shares of DBV Technologies to a “strong-buy” rating in a report on Monday, December 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of DBV Technologies in a research report on Monday, December 8th. Zacks Research raised shares of DBV Technologies from a “strong sell” rating to a “hold” rating in a research note on Monday, September 29th. Wall Street Zen upgraded shares of DBV Technologies from a “sell” rating to a “hold” rating in a report on Friday, November 28th. Finally, Guggenheim reaffirmed a “buy” rating and set a $51.00 price target (up from $35.00) on shares of DBV Technologies in a research report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $35.38.

DBV Technologies Price Performance

DBV Technologies stock opened at $22.76 on Wednesday. The company has a market cap of $914.04 million, a price-to-earnings ratio of -4.40 and a beta of -1.10. DBV Technologies has a 12 month low of $2.92 and a 12 month high of $26.18. The stock’s 50-day moving average is $15.38 and its 200-day moving average is $11.83.

Insider Transactions at DBV Technologies

In related news, major shareholder Bpifrance Epic sold 1,292,103 shares of DBV Technologies stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $4.19, for a total transaction of $5,413,911.57. Following the sale, the insider owned 7,303,369 shares of the company’s stock, valued at $30,601,116.11. The trade was a 15.03% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.44% of the stock is owned by company insiders.

Institutional Trading of DBV Technologies

Several large investors have recently modified their holdings of the business. New York State Common Retirement Fund purchased a new stake in shares of DBV Technologies during the third quarter worth about $34,000. Two Sigma Investments LP acquired a new stake in DBV Technologies during the 3rd quarter valued at approximately $167,000. Citadel Advisors LLC purchased a new stake in DBV Technologies during the 3rd quarter worth approximately $220,000. DLD Asset Management LP acquired a new position in shares of DBV Technologies in the 3rd quarter valued at approximately $250,000. Finally, Nan Fung Trinity HK Ltd. acquired a new position in shares of DBV Technologies in the 2nd quarter valued at approximately $340,000. 71.74% of the stock is currently owned by institutional investors and hedge funds.

DBV Technologies News Roundup

Here are the key news stories impacting DBV Technologies this week:

• Positive Sentiment: Phase‑III win in peanut allergy improves commercial/clinical outlook — a Bioworld report says DBV’s VIT® program delivered a positive Phase III result, a material de‑risking event for a lead program that can drive future revenue and re‑rating. Vitesse finesse pays off: DBV wins in peanut allergy phase III
• Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts, signaling stronger long‑term profitability expectations (FY2027–FY2029 upgrades). That upward revision likely helped investor sentiment and price momentum. HC Wainwright Expects Stronger Earnings for DBV Technologies
• Positive Sentiment: Additional bullish analyst notes and coverage changes — the stock was reported to hit a new 1‑year high after analyst upgrades, and coverage consensus sits around a “Moderate Buy,” with at least one firm (Citizens JMP) forecasting strong price appreciation. Those actions typically boost retail/institutional interest. DBV Technologies (NASDAQ:DBVT) Hits New 1-Year High Following Analyst Upgrade
• Neutral Sentiment: Market consensus EPS remains deeply negative for the current year (consensus ~($7.05) EPS), so while upgrades are meaningful, the company is still transitioning from loss‑making to profitable — investors should watch upcoming milestones and cash runway closely.
• Negative Sentiment: Major shareholder Bpifrance Epic sold large blocks of stock on Dec 17–18 (combined ~3.37M shares sold across two days, materially reducing its stake). Large insider/major‑holder selling can pressure the stock and signal liquidity‑driven exits even when fundamentals improve. SEC filing: Bpifrance Epic Insider Sales SEC Filing
• Negative Sentiment: Lifesci Capital trimmed its FY2026 EPS estimate (worse near‑term profitability view), a reminder that boutique analysts still see near‑term execution and cash burn risk — this can cap upside until revenue/profitability is proven.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.